Compare FPS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPS | CORT |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.7B |
| IPO Year | 2026 | 2001 |
| Metric | FPS | CORT |
|---|---|---|
| Price | $24.36 | $86.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $54.67 | ★ $141.00 |
| AVG Volume (30 Days) | ★ 8.3M | 649.2K |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | ★ $1,420,059,000.00 | $761,407,000.00 |
| Revenue This Year | $79.09 | $50.53 |
| Revenue Next Year | $33.96 | $48.90 |
| P/E Ratio | ★ $526.99 | $1,194.51 |
| Revenue Growth | ★ 88.54 | 12.79 |
| 52 Week Low | $23.16 | $28.66 |
| 52 Week High | $66.00 | $126.38 |
| Indicator | FPS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 24.86 |
| Support Level | N/A | $77.38 |
| Resistance Level | $40.48 | $122.93 |
| Average True Range (ATR) | 2.42 | 6.12 |
| MACD | -1.46 | -2.51 |
| Stochastic Oscillator | 6.58 | 7.50 |
Forgent Power Solutions Inc is a designer and manufacturer of electrical distribution equipment used in data centers, the power grid and energy-intensive industrial facilities. It manufacture and sell include automatic transfer switches (ATS), dry type transformers, electrical houses (eHouse), generator connection cabinets, liquid filled transformers, panelboards, power distribution units (PDU), power skids, remote power panels (RPP), switchboards, switchgear, and tap boxes. The company is organized and operates as one reportable segment, which carries out business activities related to the design, development, manufacturing, and marketing of products and services.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.